Josep Gumà

2.5k total citations
64 papers, 1.1k citations indexed

About

Josep Gumà is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Surgery. According to data from OpenAlex, Josep Gumà has authored 64 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 20 papers in Pathology and Forensic Medicine and 18 papers in Surgery. Recurrent topics in Josep Gumà's work include Lymphoma Diagnosis and Treatment (17 papers), Testicular diseases and treatments (14 papers) and Urologic and reproductive health conditions (9 papers). Josep Gumà is often cited by papers focused on Lymphoma Diagnosis and Treatment (17 papers), Testicular diseases and treatments (14 papers) and Urologic and reproductive health conditions (9 papers). Josep Gumà collaborates with scholars based in Spain, United Kingdom and China. Josep Gumà's co-authors include Joan Borràs, Sandra Guaita‐Esteruelas, L. Masana, Xavier García del Muro, Pablo Maroto, Jorge Aparicio, José Ángel Arranz, Luis Paz‐Ares, Joan Carles and J.R. Germà and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Josep Gumà

59 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Josep Gumà Spain 18 524 386 269 244 210 64 1.1k
Ji‐Youn Sung South Korea 21 355 0.7× 400 1.0× 136 0.5× 221 0.9× 309 1.5× 90 1.4k
Branca Cavaco Portugal 28 286 0.5× 594 1.5× 168 0.6× 150 0.6× 270 1.3× 67 2.2k
Tatsuru Ikeda Japan 17 213 0.4× 306 0.8× 215 0.8× 66 0.3× 310 1.5× 56 1.2k
Paolo Cotzia United States 17 104 0.2× 364 0.9× 149 0.6× 272 1.1× 439 2.1× 34 1.1k
Elham Khanafshar United States 21 529 1.0× 292 0.8× 58 0.2× 152 0.6× 160 0.8× 48 1.6k
Thomas Papathomas Greece 18 383 0.7× 164 0.4× 76 0.3× 329 1.3× 114 0.5× 47 962
Jeff White United Kingdom 16 209 0.4× 332 0.9× 49 0.2× 77 0.3× 279 1.3× 53 898
F Sellner Austria 13 559 1.1× 283 0.7× 139 0.5× 52 0.2× 485 2.3× 34 1.1k
Lan L. Gellert United States 17 329 0.6× 409 1.1× 39 0.1× 212 0.9× 191 0.9× 30 959

Countries citing papers authored by Josep Gumà

Since Specialization
Citations

This map shows the geographic impact of Josep Gumà's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Josep Gumà with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Josep Gumà more than expected).

Fields of papers citing papers by Josep Gumà

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Josep Gumà. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Josep Gumà. The network helps show where Josep Gumà may publish in the future.

Co-authorship network of co-authors of Josep Gumà

This figure shows the co-authorship network connecting the top 25 collaborators of Josep Gumà. A scholar is included among the top collaborators of Josep Gumà based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Josep Gumà. Josep Gumà is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Correig, Eudald, et al.. (2024). Easy‐Amanida: An R Shiny application for the meta‐analysis of aggregate results in clinical metabolomics using Amanida and Webchem. Research Synthesis Methods. 15(4). 687–699. 1 indexed citations
2.
Gumà, Josep, et al.. (2023). A Metabolites Merging Strategy (MMS): Harmonization to Enable Studies’ Intercomparison. Metabolites. 13(12). 1167–1167. 1 indexed citations
3.
Fernández‐Castillejo, Sara, Bárbara Roig, Mireia Melé, et al.. (2023). Opportunistic genetic screening increases the diagnostic yield and is medically valuable for care of patients and their relatives with hereditary cancer. Journal of Medical Genetics. 61(1). 69–77.
4.
Gumà, Josep, et al.. (2023). Blood Liquid Biopsy in an Advanced Medullary Thyroid Carcinoma: A Case Study with Rearranged during Transfection Heterogeneity. Pathobiology. 90(4). 281–288. 2 indexed citations
5.
Gumà, Josep, Gloria Marquina, Noelia Martínez-Jáñez, et al.. (2022). Increased Quality of Life in Patients with Breakthrough Cancer Pain after Individualized Therapy: the CAVIDIOM Study. Future Oncology. 18(35). 3913–3927. 3 indexed citations
6.
Llanos, Marta, Fernando Franco, Sagrario Gómez, et al.. (2022). Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study. Clinical Cancer Research. 29(1). 209–220. 30 indexed citations
7.
Gumà, Josep, Francesc Riu, Anna Hernández‐Aguilera, et al.. (2022). Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples. Cancers. 14(23). 5859–5859.
8.
9.
Franco, Fernando, M. Guirado, Natividad Martínez-Banaclocha, et al.. (2021). Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel). Current Oncology. 28(2). 1249–1255. 1 indexed citations
10.
Avilés‐Jurado, Francesc Xavier, Carmen Muñoz, Josep Gumà, et al.. (2020). Circulating microRNAs modulating glycolysis as non-invasive prognostic biomarkers of HNSCC. European Archives of Oto-Rhino-Laryngology. 278(5). 1585–1594. 6 indexed citations
11.
Rubió‐Casadevall, Jordi, Jaume Galcerán, Alberto Ameijide, et al.. (2020). Population-based risk assessment of second primary cancers following a first head and neck cancer: patterns of association and difficulties of its analysis. Clinical & Translational Oncology. 23(4). 788–798. 3 indexed citations
12.
13.
Aparicio, Jorge, Alfonso Sánchez‐Muñoz, Josep Gumà, et al.. (2018). A Risk-Adapted Approach to Patients with Stage I Seminoma according to the Status of Rete Testis: The Fourth Spanish Germ Cell Cancer Group Study. Oncology. 95(1). 8–12. 10 indexed citations
14.
Sirgo, Agustina, et al.. (2009). Deterioro cognitivo inducido por los tratamientos oncológicos sistémicos en el cáncer de mama no metastático: revisión de estudios. SHILAP Revista de lepidopterología. 3 indexed citations
15.
Marcos‐Gragera, Rafael, Josep Gumà, & Sílvia de Sanjosé. (2008). Análisis de la incidencia, la supervivencia y la mortalidad según las principales localizaciones tumorales, 1985-2019: linfomas no Hodgkin. Medicina Clínica. 131. 72–77. 3 indexed citations
16.
Aparicio, Jorge, J.R. Germà, Xavier García del Muro, et al.. (2005). Risk-Adapted Management for Patients With Clinical Stage I Seminoma: The Second Spanish Germ Cell Cancer Cooperative Group Study. Journal of Clinical Oncology. 23(34). 8717–8723. 134 indexed citations
17.
Gumà, Josep, et al.. (2004). Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Annals of Oncology. 15(12). 1798–1804. 51 indexed citations
18.
Aparicio, Jorge, Xavier García del Muro, Pablo Maroto, et al.. (2003). Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Annals of Oncology. 14(6). 867–872. 78 indexed citations
19.
Muro, Xavier García del, E. Marcuello, Josep Gumà, et al.. (2002). Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. British Journal of Cancer. 86(3). 326–330. 34 indexed citations
20.
Rueda, Antonio, Isabel Sevilla, Josep Gumà, et al.. (2001). Secondary Prophylactic G-CSF (Filgrastim) Administration in Chemotherapy of Stage I and II Hodgkin's Lymphoma with ABVD. Leukemia & lymphoma. 41(3-4). 353–358. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ji‐Youn Sung Breakdown of academic impact, for papers by Branca Cavaco Breakdown of academic impact, for papers by Tatsuru Ikeda Breakdown of academic impact, for papers by Paolo Cotzia Breakdown of academic impact, for papers by Elham Khanafshar Breakdown of academic impact, for papers by Thomas Papathomas Breakdown of academic impact, for papers by Jeff White Breakdown of academic impact, for papers by F Sellner Breakdown of academic impact, for papers by Lan L. Gellert
Rankless by CCL
2026